Form 4: Protalix Director Awarded New Equity Compensation

Protalix BioTherapeutics director Pol F. Boudes received 7,500 restricted shares and 15,000 stock options as equity compensation.

Summary

• Pol F. Boudes, a Director of Protalix BioTherapeutics, Inc. (PLX), was awarded 7,500 restricted shares of common stock and 15,000 stock options on September 3, 2025.
• The restricted shares are held indirectly by a Trust for tax benefits under Section 102 of the Israeli Tax Ordinance.
• Both the restricted shares and the stock options will vest in 12 equal quarterly installments, commencing from the grant date of September 3, 2025.
• The stock options have an exercise price of $1.64 per share and expire on September 3, 2035.
• This award is made under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended.

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation for a director, which is a standard practice to align management and shareholder interests. It is a neutral to slightly positive event as it reinforces governance and incentive structures.

Positives

• The award of restricted shares and stock options to a director aligns their interests with those of the shareholders, incentivizing long-term performance.
• The compensation is issued under an established and amended stock incentive plan, indicating structured corporate governance around equity awards.

Future Outlook

The restricted shares and stock options will vest in 12 equal quarterly installments commencing from the grant date of September 3, 2025, indicating a future schedule for the director's equity ownership to become fully realized.

Industry Context

Equity compensation, including restricted stock and stock options, is a common practice in the biotechnology industry to attract, retain, and incentivize key personnel, including directors, by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• The use of restricted stock and stock options for director compensation is a standard practice across the biotechnology and broader corporate landscape, aiming to align director incentives with shareholder value.
• The vesting schedule over 12 quarterly installments is a typical mechanism to encourage long-term commitment and performance, comparable to similar plans at companies like BioNTech or Moderna for their non-executive directors, though specific award sizes vary based on company size and individual roles.

Corporate Governance

Related Party Transactions

• The transaction involves the award of equity compensation to Pol F. Boudes, a director of Protalix BioTherapeutics, Inc., which constitutes a related party transaction as part of his compensation package.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacted, the existence of a stock incentive plan can set a precedent for broader employee incentive programs.

Next Steps

• The restricted shares and stock options will vest in 12 equal quarterly installments, commencing from September 3, 2025.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director and does not provide new information that would significantly alter the investment thesis for Protalix BioTherapeutics. It reflects standard corporate governance practices for aligning director incentives with shareholder value, thus warranting no change from a 'hold' recommendation based solely on this disclosure.

Keywords

Protalix BioTherapeutics, PLX, Form 4, Insider Transaction, Equity Compensation, Restricted Stock, Stock Options, Director Compensation, Boudes Pol F